Skip to main content

Table 4 Multivariate analysis of prognostic factors for locally advanced NPC

From: Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy

Endpoint Variable Regression coefficient Standard error P value HR 95% CI
OS Age (<50 vs. ≥50 years) 0.793 0.251 0.002 2.209 1.350–3.616
T category (T3 vs. T4) 0.134 0.452 0.766 1.144 0.472–2.775
N category (N0 vs. N1 vs. N2 vs. N3) 0.364 0.133 0.006 1.439 1.108–1.868
Sex (male vs. female) −0.168 0.278 0.547 0.845 0.490–1.459
Pathologic type (WHO I vs. II–III) 0.415 0.473 0.380 1.515 0.599–3.830
Chemotherapy (yes vs. no) −0.409 0.484 0.398 0.664 0.257–1.716
Radiation dose (<73.92 vs. ≥73.92 Gy) −0.189 0.437 0.666 0.828 0.352–1.950
GTV-P (≤46.4 vs. >46.4 mL) 0.901 0.261 0.001 2.463 1.478–4.104
LRFS Age (<50 vs. ≥50 years) 1.768 0.578 0.002 5.857 1.887–18.186
T category (T3 vs. T4) −0.151 0.801 0.851 0.86 0.179–4.133
N category (N0 vs. N1 vs. N2 vs. N3) −0.108 0.249 0.663 0.897 0.551–1.462
Sex (male vs. female) 0.150 0.571 0.793 1.162 0.379–3.557
Pathologic type (WHO I vs. II-III) 0.355 0.765 0.643 1.426 0.318–6.391
Chemotherapy (yes vs. no) −0.369 0.776 0.634 0.691 0.151–3.165
Radiation dose (<73.92 vs. ≥73.92 Gy) −0.659 1.038 0.525 0.517 0.068–3.956
GTV-P (≤46.4 vs. >46.4 mL) 1.029 0.520 0.048 2.798 1.010–7.746
DMFS Age (< 50 vs. ≥ 50 years) 0.252 0.281 0.370 1.287 0.741–2.234
T category (T3 vs. T4) 0.559 0.543 0.303 1.749 0.604–5.068
N category (N0 vs. N1 vs. N2 vs. N3) 0.418 0.147 0.005 1.519 1.138–2.027
Sex (male vs. female) −0.132 0.303 0.664 0.877 0.485–1.586
Pathologic type (WHO I vs. II-III) 0.255 0.525 0.627 1.291 0.461–3.611
Chemotherapy (yes vs. no) −0.178 0.613 0.771 0.837 0.252–2.780
Radiation dose (<73.92 vs. ≥73.92 Gy) −0.024 0.440 0.956 0.976 0.412–2.313
GTV-P (≤46.4 vs. >46.4 mL) 0.963 0.280 0.001 2.620 1.514–4.534
DFS Age (<50 vs. ≥50 years) 0.535 0.225 0.018 1.708 1.098–2.656
T category (T3 vs. T4) 0.376 0.415 0.365 1.457 0.646–3.286
N category (N0 vs. N1 vs. N2 vs. N3) 0.287 0.118 0.015 1.333 1.057–1.680
Sex (male vs. female) −0.114 0.251 0.649 0.892 0.545–1.459
Pathological type (WHO I vs. II-III) 0.423 0.401 0.292 1.526 0.695–3.350
Chemotherapy (yes vs. no) −0.337 0.441 0.445 0.714 0.301–1.694
Radiation dose (< 73.92 vs. ≥ 73.92 Gy) −0.105 0.379 0.781 0.900 0.428–1.891
GTV-P (≤ 46.4 vs. > 46.4 mL) 0.848 0.230 <0.001 2.335 1.487–3.667
  1. HR hazard ratio, CI confidence interval, OS overall survival, LRFS local relapse-free survival, DMFS distant metastasis-free survival, DFS disease-free survival
  2. P values were calculated using an adjusted Cox proportional hazards model